Role of Sclerostin in Mastocytosis Bone Disease
Author Information
Author(s): Szudy-Szczyrek Aneta, Mlak Radosław, Pigoń-Zając Dominika, Krupski Witold, Mazurek Marcin, Tomczak Aleksandra, Chromik Karolina, Górska Aleksandra, Koźlik Paweł, Juda Adrian, Kokoć Anna, Dubaj Maciej, Sacha Tomasz, Niedoszytko Marek, Helbig Grzegorz, Szczyrek Michał, Szumiło Justyna, Małecka-Massalska Teresa, Hus Marek
Primary Institution: Medical University of Lublin
Hypothesis
The study investigates whether neoplastic mast cells may be the source of sclerostin and its association with bone remodeling markers in mastocytosis-related bone disease.
Conclusion
Sclerostin may serve as a marker of more advanced disease and bone disease in mastocytosis.
Supporting Evidence
- Human mast cells can secrete sclerostin.
- IL-6 stimulation significantly increases SOST gene expression.
- Patients with advanced mastocytosis have higher sclerostin levels.
- Significant correlation between sclerostin and alkaline phosphatase concentrations.
- Patients with increased sclerosis of spongy bone have higher sclerostin concentrations.
Takeaway
This study found that a protein called sclerostin, made by certain cells in the body, can help show how serious a bone disease related to mastocytosis is.
Methodology
The study assessed sclerostin levels in plasma from 39 mastocytosis patients and in human mast cell cultures, using ELISA and gene expression analysis.
Limitations
The study group was relatively small, and comorbidities were not fully described.
Participant Demographics
The median age of participants was 49 years, with a slight majority being women (56.4%).
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website